JP2011525388A - 緑内障の併用治療 - Google Patents

緑内障の併用治療 Download PDF

Info

Publication number
JP2011525388A
JP2011525388A JP2011514898A JP2011514898A JP2011525388A JP 2011525388 A JP2011525388 A JP 2011525388A JP 2011514898 A JP2011514898 A JP 2011514898A JP 2011514898 A JP2011514898 A JP 2011514898A JP 2011525388 A JP2011525388 A JP 2011525388A
Authority
JP
Japan
Prior art keywords
latanoprost
delivery system
eye
days
punctal plug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011514898A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011525388A5 (US20050271705A1-20051208-C00006.png
Inventor
ブトゥーナー，ズハル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QLT Plug Delivery Inc
Original Assignee
QLT Plug Delivery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by QLT Plug Delivery Inc filed Critical QLT Plug Delivery Inc
Publication of JP2011525388A publication Critical patent/JP2011525388A/ja
Publication of JP2011525388A5 publication Critical patent/JP2011525388A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)
JP2011514898A 2008-06-24 2009-06-24 緑内障の併用治療 Pending JP2011525388A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7528408P 2008-06-24 2008-06-24
US61/075,284 2008-06-24
PCT/US2009/048452 WO2010008883A1 (en) 2008-06-24 2009-06-24 Combination treatment of glaucoma

Publications (2)

Publication Number Publication Date
JP2011525388A true JP2011525388A (ja) 2011-09-22
JP2011525388A5 JP2011525388A5 (US20050271705A1-20051208-C00006.png) 2012-08-02

Family

ID=41431875

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011514898A Pending JP2011525388A (ja) 2008-06-24 2009-06-24 緑内障の併用治療

Country Status (7)

Country Link
US (1) US20090318549A1 (US20050271705A1-20051208-C00006.png)
EP (1) EP2303184A4 (US20050271705A1-20051208-C00006.png)
JP (1) JP2011525388A (US20050271705A1-20051208-C00006.png)
CN (1) CN102105118A (US20050271705A1-20051208-C00006.png)
CA (1) CA2728623A1 (US20050271705A1-20051208-C00006.png)
TW (1) TW201012469A (US20050271705A1-20051208-C00006.png)
WO (1) WO2010008883A1 (US20050271705A1-20051208-C00006.png)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016506931A (ja) * 2013-01-24 2016-03-07 ライジェル ファーマシューティカルズ， インコーポレイテッド 点眼用組成物
WO2016047366A1 (ja) * 2014-09-22 2016-03-31 株式会社カネカ 内視鏡用注射器具
JP2021530253A (ja) * 2018-03-29 2021-11-11 マティ セラピューティクス，インク． 眼科用徐放性製剤およびドライアイ症候群治療のための使用

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006014434A2 (en) 2004-07-02 2006-02-09 Eliot Lazar Treatment medium delivery device and methods for delivery
CN103393496B (zh) 2006-03-31 2016-08-17 玛提治疗有限公司 用于药物治疗的鼻泪引流系统植入物
WO2009035571A2 (en) 2007-09-07 2009-03-19 Qlt Plug Delivery, Inc Lacrimal implant detection
JP2011520805A (ja) 2008-05-09 2011-07-21 キューエルティー プラグ デリバリー，インク． 緑内障および高眼圧症治療のための活性剤の持続送達
EP4108216A1 (en) 2009-06-03 2022-12-28 Forsight Vision5, Inc. Anterior segment drug delivery
SG187770A1 (en) 2010-08-12 2013-03-28 Univ Nanyang Tech A liposomal formulation for ocular drug delivery
US8591484B2 (en) 2010-09-15 2013-11-26 AlphaMed, Inc. Lacrimal punctum measurement and occlusion
US20120312840A1 (en) * 2011-05-13 2012-12-13 Ayako Hasegawa Container closure system with integral antimicrobial additives
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
ES2727203T3 (es) 2011-08-29 2019-10-14 Mati Therapeutics Inc Administración por liberación sostenida de agentes activos para tratar glaucoma e hipertensión ocular
RU2740680C2 (ru) 2011-09-14 2021-01-19 Форсайт Вижн5, Инк. Глазное вкладочное устройство и способы
US9750636B2 (en) 2012-10-26 2017-09-05 Forsight Vision5, Inc. Ophthalmic system for sustained release of drug to eye
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
US9424722B2 (en) * 2014-05-14 2016-08-23 Unlimited Liability, LLC Smart memory material lock devices
RU2562515C1 (ru) * 2014-08-19 2015-09-10 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Интубационный набор для биканаликулярного дренирования слезоотводящих путей
EP3223793B1 (en) 2014-11-25 2023-06-28 Eximore Ltd. Compositions and methods for delivering a bio-active agent or bio-active agents
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
US11291847B2 (en) * 2015-06-16 2022-04-05 The Regents Of The University Of Colorado, A Body Corporate Systems and methods for preventing, diagnosing, and/or treating one or more medical conditions via neuromodulation
CN105879126A (zh) * 2016-03-24 2016-08-24 杭州亚慧生物科技有限公司 一种超润滑血清白蛋白泪点塞及其制备方法
CN109568138B (zh) * 2019-01-10 2021-06-25 新疆国际旅行卫生保健中心 药片分割装置
US11207267B2 (en) 2019-10-02 2021-12-28 Segal Innovations LLC Bio-adhesive dissolving compounds and device

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070269487A1 (en) * 2006-03-31 2007-11-22 Forsight Labs, Llc Drug Delivery Methods, Structures, and Compositions for Nasolacrimal System
JP2007535537A (ja) * 2004-04-30 2007-12-06 アラーガン、インコーポレイテッド プロスタミド含有生分解性眼内インプラント

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281654A (en) * 1980-04-07 1981-08-04 Alza Corporation Drug delivery system for controlled ocular therapy
US5589563A (en) * 1992-04-24 1996-12-31 The Polymer Technology Group Surface-modifying endgroups for biomedical polymers
DK0637323T3 (da) * 1992-04-24 1999-05-25 Polymer Technology Group Inc Copolymerer og ikke-porøs, semipermeabel membran deraf og dens anvendelse til permeering af molekyler med et forudbestemt m
US6196993B1 (en) * 1998-04-20 2001-03-06 Eyelab Group, Llc Ophthalmic insert and method for sustained release of medication to the eye
ES2172415B2 (es) * 2000-07-28 2003-11-16 Univ Madrid Complutense Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
AU2004207506B2 (en) * 2003-01-24 2009-10-08 Psivida Us Inc. Sustained release device and method for ocular delivery of adrenergic agents
WO2004075781A2 (en) * 2003-02-26 2004-09-10 Medivas, Llc Bioactive stents and methods for use thereof
US7662864B2 (en) * 2003-06-04 2010-02-16 Rutgers, The State University Of New Jersey Solution polymerization processes to prepare a polymer that degrades to release a physiologically active agent
US20050129731A1 (en) * 2003-11-03 2005-06-16 Roland Horres Biocompatible, biostable coating of medical surfaces
US20050232972A1 (en) * 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
US20070197491A1 (en) * 2005-10-14 2007-08-23 Alcon, Inc. Method for treating primary and secondary forms of glaucoma
JP5323720B2 (ja) * 2006-12-18 2013-10-23 アルコン リサーチ， リミテッド 眼用薬物送達のためのデバイスおよび方法
UY30883A1 (es) * 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
WO2009035567A2 (en) * 2007-09-07 2009-03-19 Qlt Plug Delivery, Inc Insertion and extraction tools for lacrimal implants
CN101984745B (zh) * 2007-09-07 2013-08-14 Qlt股份有限公司 用于持续释放治疗药物的药物核心
CA2698508C (en) * 2007-09-07 2017-06-06 Alan R. Rapacki Lacrimal implants and related methods
MX2010008998A (es) * 2008-02-18 2010-11-26 Qlt Plug Delivery Inc Implantes lagrimales y metodos relacionados.
WO2009134371A2 (en) * 2008-04-30 2009-11-05 Qlt Plug Delivery, Inc. Composite lacrimal insert and related methods
JP2011520805A (ja) * 2008-05-09 2011-07-21 キューエルティー プラグ デリバリー，インク． 緑内障および高眼圧症治療のための活性剤の持続送達

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007535537A (ja) * 2004-04-30 2007-12-06 アラーガン、インコーポレイテッド プロスタミド含有生分解性眼内インプラント
US20070269487A1 (en) * 2006-03-31 2007-11-22 Forsight Labs, Llc Drug Delivery Methods, Structures, and Compositions for Nasolacrimal System

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6013063689; ＰＡＴＥＬ，　Ｓ．　Ｓ．　ｅｔ　ａｌ: 'ＬＡＴＡＮＯＰＲＯＳＴ　Ａ　ＲＥＶＩＥＷ　ＯＦ　ＩＴＳ　ＰＨＡＲＭＡＣＯＬＯＧＩＣＡＬ　ＰＲＯＰＥＲＩＴＥＳ，　ＣＬＩＮＩＣＡＬ　ＥＦＦＩＣＡＣＹ　ＡＮＤ　ＴＯＬＥＲＡＢＩＬＩＴＹ　ＩＮ　ＴＨＥ　ＭＡ' ＤＲＵＧＳ　＆　ＡＧＩＮＧ Ｖｏｌ．９，　Ｎｏ．５, 1996, ｐ．３６３-３７８ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016506931A (ja) * 2013-01-24 2016-03-07 ライジェル ファーマシューティカルズ， インコーポレイテッド 点眼用組成物
WO2016047366A1 (ja) * 2014-09-22 2016-03-31 株式会社カネカ 内視鏡用注射器具
JPWO2016047366A1 (ja) * 2014-09-22 2017-06-29 株式会社カネカ 内視鏡用注射器具
JP2021530253A (ja) * 2018-03-29 2021-11-11 マティ セラピューティクス，インク． 眼科用徐放性製剤およびドライアイ症候群治療のための使用

Also Published As

Publication number Publication date
TW201012469A (en) 2010-04-01
CA2728623A1 (en) 2010-01-21
US20090318549A1 (en) 2009-12-24
EP2303184A1 (en) 2011-04-06
EP2303184A4 (en) 2013-06-19
WO2010008883A1 (en) 2010-01-21
CN102105118A (zh) 2011-06-22

Similar Documents

Publication Publication Date Title
US20200323685A1 (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
JP2011525388A (ja) 緑内障の併用治療
TWI454285B (zh) 治療青光眼及高眼壓之活性劑之持續釋放輸送
JP5885244B2 (ja) １つまたは複数の薬剤の徐放性送達
US20100274224A1 (en) Lacrimal implant body including comforting agent
US20140025022A1 (en) Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
JP6213560B2 (ja) 薬剤送達システムならびに開放隅角緑内障および高眼圧症を治療する方法

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120615

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140107

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140722